Drugs / synthetic human papillomavirus 16 E6 peptide
synthetic human papillomavirus 16 E6 peptide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00019110 | Nov 1995 → ? | anus cancer, cervical cancer, esophageal cancer, head and neck cancer +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00002916 | Nov 1996 → ? | cervical cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | synthetic human papillomavirus 16 E6 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002916 ↗ |
| Modality | Peptide | “synthetic human papillomavirus 16 E6 peptide” NCT00002916 ↗ |
| Route | Intravenous | “Patients receive vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes” NCT00019110 ↗ |